IMCT-17STATISTICALLY SIGNIFICANT ASSOCIATION OF GLIOBLASTOMA IMMUNOTHERAPY PHASE II CLINICAL STUDY (ICT-107) TREATMENT AND SURVIVAL TO IMMUNE RESPONSE USING A NOVEL COMPREHENSIVE ELISPOT ANALYSIS
Article
Santos, Radleigh, Gringeri, Anthony, Yu, John et al. (2015). IMCT-17STATISTICALLY SIGNIFICANT ASSOCIATION OF GLIOBLASTOMA IMMUNOTHERAPY PHASE II CLINICAL STUDY (ICT-107) TREATMENT AND SURVIVAL TO IMMUNE RESPONSE USING A NOVEL COMPREHENSIVE ELISPOT ANALYSIS
. NEURO-ONCOLOGY, 17(suppl_5), v111-v111. 10.1093/neuonc/nov218.17
Santos, Radleigh, Gringeri, Anthony, Yu, John et al. (2015). IMCT-17STATISTICALLY SIGNIFICANT ASSOCIATION OF GLIOBLASTOMA IMMUNOTHERAPY PHASE II CLINICAL STUDY (ICT-107) TREATMENT AND SURVIVAL TO IMMUNE RESPONSE USING A NOVEL COMPREHENSIVE ELISPOT ANALYSIS
. NEURO-ONCOLOGY, 17(suppl_5), v111-v111. 10.1093/neuonc/nov218.17